Acutaas Chemicals Limited

rs,

rat, India. January 28, 2025 To, The Listing Department, BSE LIMITED, Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai- 400 001 To, The Listing Department National Stock Exchange of India

698 crore

delighted to share that in the first nine months of FY25, we achieved revenue of entire previous 698 crore, financial year. In Q3FY25 alone, we delivered an impressive 65.2% year-on-year growth, achieving

65.2%

evenue of entire previous 698 crore, financial year. In Q3FY25 alone, we delivered an impressive 65.2% year-on-year growth, achieving X275 crore in revenue from operations. This performance was driven

275 crore

financial year. In Q3FY25 alone, we delivered an impressive 65.2% year-on-year growth, achieving X275 crore in revenue from operations. This performance was driven by a strong advanced pharmaceutical inte

30%

rs. With improved visibility for Q4, | am pleased to revise our FY25 growth guidance upward from 30% to 35%. This milestone reflects our unwavering commitment to delivering consistent progress, embra

35%

ith improved visibility for Q4, | am pleased to revise our FY25 growth guidance upward from 30% to 35%. This milestone reflects our unwavering commitment to delivering consistent progress, embracing ad

Rs. 2,750

ss Highlights > > > > > > » Revenue from operations for Q3FY25 grew by 65.2% YoY to Rs. 2,750 mn The gross margin for the quarter improved to 46.2% up 333 bps YoY and 281 bps QoQ EBITDA for

46.2%

rations for Q3FY25 grew by 65.2% YoY to Rs. 2,750 mn The gross margin for the quarter improved to 46.2% up 333 bps YoY and 281 bps QoQ EBITDA for the quarter came at Rs. 687 mn up 159.0% YoY compared

333 bps

or Q3FY25 grew by 65.2% YoY to Rs. 2,750 mn The gross margin for the quarter improved to 46.2% up 333 bps YoY and 281 bps QoQ EBITDA for the quarter came at Rs. 687 mn up 159.0% YoY compared to Rs. 265

281 bps

y 65.2% YoY to Rs. 2,750 mn The gross margin for the quarter improved to 46.2% up 333 bps YoY and 281 bps QoQ EBITDA for the quarter came at Rs. 687 mn up 159.0% YoY compared to Rs. 265 mn in Q3FY24.

Rs. 687

for the quarter improved to 46.2% up 333 bps YoY and 281 bps QoQ EBITDA for the quarter came at Rs. 687 mn up 159.0% YoY compared to Rs. 265 mn in Q3FY24. EBITDA margin for the quarter was at 25.0% as

159.0%

er improved to 46.2% up 333 bps YoY and 281 bps QoQ EBITDA for the quarter came at Rs. 687 mn up 159.0% YoY compared to Rs. 265 mn in Q3FY24. EBITDA margin for the quarter was at 25.0% as compared to

“2023 2028E ¥ Oncology ® Cardiovascular ® CNS ® Anti-Infective ® Immunology * Endocrinology * Anti-Coagulant * Gastrointestinal = Anti-Depressant ~ Parkinson's Disease ~ Others Note: E indicates Estimate Source: F&S Report CAGR CAGR (2018-23) (2023-28E) Oncology 11% 13% 25% o Cardiovascular CNS 9% Anti-Infective Immunology Endocrinology Anti-Coagulant Gastrointestinal Anti-Depressant Parkinson’s Disease 4% 6% 4% 8% 8% 8% 4% 4% 7% 5% 5% 5% 9% 7% 8% 5% 3% 8% 32 4.”

“Historical Business Performance (INR mn) CAGR 112% I I 8% 340+ Customers g 40+ .”

“Development and entry into newer applications having strong entry barriers Continue to work on improving operational efficiencies to deliver better margins Leverage the technology and capability of Baba Fine Chemicals to expand the semiconductor chemical business Grow the Battery Chemicals segment - Electrolyte additives sample approved at plant scale from 6 customers 35 Industry Overview (2/ Global Specialty Chemicals Market (USD bn) 36% CAGR /;37 785 ® AMI ORGANICS LTD.”

“(USD bn) R s 11.2 6.5 0.8 2018 148%CAGR 1.6 2023 125%CACR 16.0% CAGR 34 2028E Electrolyte Additives Electrolyte Solutions (USD bn) STRCAGR 515 a_(WoCAfiR 68.9 39.0 1.9 2018 48%CAGR 5.5% CAGR 23 2023 31 2028E Photoresist Chemicals Semiconductor Chemicals 36 Note: E indicates Estimate Source: F&S Report AMI ORGANICS LTD.”

Focused on the development and manufacturing of

1

For more information please contact

1

Focused on the development and manufacturing of

oo@? 20\ ? * Advanced Pharmaceutical Intermediates . . Speaalty Chemicals ‘ Serves diverse end-use industries including Pharmaceuticals, Cosmetics, Fine Chemicals, Semiconductor, Battery Chemicals, among others Advanced Pharmaceutical Intermediates Specialty Chemicals Revenue Mix (FY24) 79% 21% i ‘ Advanced Pharmaceutical Intermediates Specialty Chemicals 570+ Products Invoiced to customers in last 5 years 15 The Evolution 0 AMI ORGANICS LTD. > 2004 2005 2006 Formation of partnership firm in the name of “Ami Organics” Guijarat Gas Safety Award — developing and implementing effective HSE Management System Change in constitution from partnership firm to private limited in the name of “Ami Organics Private Limited” 2011 Implemented the Integrated Management System 2017 — Achieved tumover of INR 1,500 mn Increased warehouse capacity, equipped with modem infrastructure & a storage capacity of 1,050 MT of RM Outstanding export performance “Second Award” Panel - I Inorganic, Organic and Agro

For more information please contact

Ami Organics Limited mosacsie. Ekta Srivastava Company Secretary & Compliance Officer Rahul Thakur Senior Manager — Investor Relations ® AMI ORGANICS LTD. © 2020 Ami Organics Limited, All Rights Reserved. 40